Study conducted in collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer SAN DIEGO, October 4, 2017 – eFFECTOR Therapeutics,...

This quiet biotech is looking for curative therapies and new vaccines for a host of infectious diseases with an experienced biopharma...

Emeryville, CA, September 26, 2017 – Gritstone Oncology, a next-generation personalized cancer immunotherapy company, has been named by...

BlackThorn Therapeutics has been selected as one of the “Fierce 15” winners for 2017. With this designation, BlackThorn is considered one...

Boston-based Indigo announced Tuesday the first closing of $156 million in its Series D financing, doubling the company’s total capital...

Proceeds Will Support Further Development of Proprietary Tumor Antigen Identification Platform and Advancement of Pipeline of...

July 26, 2017 at 7:30 PM EDT WESTLAKE VILLAGE, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA)...

July 24, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators for the treatment of cancer,...

South San Francisco, Calif. – June 20, 2017 – BlackThorn Therapeutics, a clinical-stage biopharmaceutical company discovering and...